It is an exciting time in the world of vasculitis research. More clinical studies and trials are being conducted now than at any time in history. In the past ten years, four drugs have been approved by the U.S. Food & Drug Administration (FDA) and other regulatory agencies specifically for the treatment of vasculitis: Rituximab…
“It’s like winning Powerball.” For months, there has been a steady trickle of questions from my patients, asking for my opinion about the new vaccines being developed to prevent COVID-19. More to the point, they want to know if they should be vaccinated. After some fits and starts, I finally struck upon a pat answer…
Rheumatology has arguably benefited like no other field from the proliferation of an increasingly effective pipeline of therapeutics. These medications have dramatically raised the bar for clinical outcomes for our patients in a way that we could not have envisioned a short generation ago. With such therapeutic progress now reaching a widening circle of rheumatic…
A proposed biomarker may improve the diagnosis of rheumatoid arthritis (RA). Writing in Arthritis & Rheumatology, researchers at Pleasanton, Calif.-based Roche Sequencing Solutions and the University of Toronto say their biomarker, constructed by profiling a comprehensive set of antibodies via high-density peptide array, has high specificity and sensitivity for RA, compared with commercially available assays.1…
The COVID-19 global pandemic has disrupted rheumatology clinics and practices all over the world. In the U.S., many providers have used telemedicine to expand access to care for their patients while managing in-person visits. Brett Smith, DO, who practices at the Blount Memorial Physicians Group, East Tennessee Children’s Hospital, Knoxville, spoke with The Rheumatologist about…
On Dec. 10, the Supreme Court of the United States of America (SCOTUS) issued a landmark decision in Rutledge, Attorney General of Arkansas, v. Pharmaceutical Care Management Association. In an 8–0 decision, the justices agreed that states have the right to impose regulations on pharmacy benefit managers (PBMs), companies that manage prescription drug benefits on…
Pandemic fatigue is affecting rheumatologists and their patients in different ways, says Nilanjana Bose, MD, MBA. But efforts are being made at her clinic to stay positive and ensure quality patient care.
Marcus Snow, MD, FACR, had his first exposure to rheumatology in a rotation during his residency at the University of Nebraska Medical Center, Omaha. James O’Dell, MD, Theodore Mikuls, MD, Jay Moore, MD, Lynn Klassen, MD, and other physicians showed how rheumatology could be the perfect mix of a narrow clinical focus with interesting patient…
It is nine months into the COVID-19 pandemic in the U.S. and the third wave is upon us, overwhelming hospital systems in many states across the country. But the alarms are being sounded for another looming pandemic as well. As early as spring 2020, significant increases were documented in the prevalence of depression and anxiety,…
Humans are not perfectly symmetrical. Almost everyone has one ear that’s higher or one foot that’s larger than the other. Similarly, leg lengths are often not quite the same. There is disagreement as to what constitutes a clinically significant difference, but some studies suggest that leg length discrepancy (LLD) can lead to osteoarthritis (OA) of…
Tumor necrosis factor-α inhibitors (TNFi’s) have emerged as an integral part of therapeutic strategies for several rheumatic diseases. TNF-α is a pro-inflammatory cytokine implicated in the pathogenesis of rheumatoid arthritis (RA), seronegative spondyloarthropathies and inflammatory bowel disease (IBD). It also plays a central role in the immune response to mycobacterial infection. Many biologic agents, particularly…
A recent pilot study explores the feasibility of virtual reality-based pain interventions for people with rheumatic conditions.1 Although the work is in its early stages, it may someday represent a new non-pharmacological tool for patients with chronic pain. VR for Treatment R. Swamy Venuturupalli, MD, FACR, is an associate clinical professor of medicine at the…
Psoriatic arthritis (PsA) has a higher life impact on women than men, suggesting the need to include life impact as part of the treat-to-target strategy for PsA. This is the finding of a recently published study by Orbai et al., which found female sex independently linked to high PsA life impact.1 The Study The study…
Three FDA representatives discuss new drug indications, safety precautions and label changes, & an emergency program to rapidly evaluate existing immunomodulating therapies for use in COVID-19 patients.
In an ACR Convergence session, two rheumatologists discussed how COVID-19 changed the use of telemedicine, how payers reacted and which changes are likely permanent and which are likely to be temporary.
In light of the release of the ACR’s new gout guideline, it’s not surprising that 50 abstracts of studies on various aspects of gout were accepted at ACR Convergence 2020. Here, we highlight just a few:
ACR Convergence panelists discussed how to monitor SSc-ILD patients for ILD severity & the brightening prospects for therapy.
The ACR Review Course featured eight talks providing a practical review of issues encountered by rheumatologists.
Reactive arthritis is classically associated with an infectious etiology, such as Salmonella, Yersinia, Campylobacter, Chlamydia or gonorrhea. Clostridium difficile is a rare, and recently recognized, causative agent for this condition.1 Case Presentation The patient is a 21-year-old man with a past medical history significant for hereditary spherocytosis and Crohn’s disease, complicated by an anorectal fistula,…
Patients who do not fulfill classification criteria for systemic lupus erythematosus (SLE) can be referred to as having probable SLE (pSLE). These patients can be identified with cell-bound complement activation products (CB-CAPs), according to a recently published study in Arthritis & Rheumatology.1 The findings are relevant because the existing Systemic Lupus Erythematosus International Collaborating Clinics…
Technological advances, including disease registries such as ACR’s RISE registry, are improving physicians’ ability to connect disparate patients with similar clinical symptoms, driving insights into both rare and common diseases.
As his term as chair of the Affiliate Society Council draws to a close, Chris Adams, MD, FACP, FACR, reflects on the personal and professional rewards of volunteer leadership and the importance and impact of coordinated state-level advocacy efforts for the future of rheumatology.
Is it taboo to talk about politics during the office visit? My morning routine may sound familiar to many of you: I wake up and get ready for work. Before I step out of my car, I put on my mask. I go inside the office to greet the staff and to get my temperature…
Peter Grayson, MD, MSc, a tenure track investigator at the National Institutes of Health (NIH) Intramural Research Program, Bethesda, Md., sometimes wonders how his life would have turned out if the band he was playing in during college had signed a recording contract with a major record label. Dr. Grayson has been playing the piano…
New Appointments for Carlos Lozada, MD In the midst of the coronavirus pandemic, Carlos J. Lozada, MD, FACP, FACR, professor of clinical medicine, University of Miami Miller School of Medicine, has expanded his professional and volunteer duties. In May he was appointed chief (interim) of the Division of Rheumatology at the Miller School of Medicine,…
Baricitinib appears to be a safe long-term treatment for RA patients, according to a recent analysis of patients with drug exposure up to eight years.
Researchers found half of patients taking the biosimilar infliximab-dyyb (Inflectra) remained highly adherent to medication use after 12 months.